… can seem gradual. Trials go through detailed procedures to get approval, recruit participants and begin. Recently, … therapy forward in the drug development pipeline. NILO-PD: Completed recruitment of Phase II nilotinib trial for … (FDA)-approved treatment for certain cancers. Previous pre-clinical research and a small, open-label Phase …

… that physicians participate in reporting, enhance the completeness and accuracy of existing data and establish … and active engagement with other PD entities will enhance access to meaningful data for use in evaluating PD … level PD programs to provide data to increase awareness, knowledge and capabilities for PD prevention, screening and …

… Leon Levine and his wife, Sandra, donated $100,000 to The Michael J. Fox … fall issue of our newsletter, Accelerating the Cure. Click here to see the entire issue. --- In 1959, Leon Levine … with $1.1 billion in revenue. Seeking to give back to the community that enabled his success, in 1980 he founded the …

… is the sudden and unpredictable inability to start moving or continue moving," says Rachel Dolhun, MD, one of our MDs on staff. "It can happen anywhere and at any time but walking through doorways and turning around are common triggers. Not only is this frustrating but it can …

… functioning (PD-PROP study). Now that reporting has grown to more than 20,000 persons, including substantial follow-up … by typing in their responses on a keyboard. We will apply computer science tools to analyze the patients’ own words to … the reports and develop a vocabulary of words that best express the patient-reported experience of PD. Impact on …

… and PARK4. Furthermore, alpha-synuclein is also the major component of Lewy bodies, the characteristic protein … likely plays an important role in the pathogenesis of PD. Pre-clinical models of alpha-synuclein-linked PD have been … nigra, the principal neurons associated with the major motor symptoms of PD, fail to adequately degenerate in these …